Price T Rowe Associates Inc Theravance Biopharma, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 55,480 shares of TBPH stock, worth $547,032. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,480
Previous 47,780
16.12%
Holding current value
$547,032
Previous $406,000
10.34%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding TBPH
# of Institutions
122Shares Held
47.3MCall Options Held
200Put Options Held
12.8K-
Madison Avenue Partners, LP New York, NY9.51MShares$93.8 Million9.44% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$73.5 Million1.94% of portfolio
-
Newtyn Management, LLC New York, NY4.5MShares$44.4 Million6.4% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$37.3 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$27.2 Million1.95% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $658M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...